Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment

Jannini, Tommaso B.; Sansone, Andrea; Rossi, Rodolfo; Lorenzo, Giorgio Di; Toscano, Massimiliano; Siracusano, Alberto; Jannini, Emmanuele A.

doi:10.1080/14656566.2022.2071124

Cited by 6 publications

(2 citation statements)

References 202 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As indicated in several studies, paliperidone could be labeled as a sexolytic agent, due to its negative impact on sexual functioning ( Montejo et al, 2021 ; Jannini et al, 2022 ). However, there is limited availability of reports regarding the impact of paliperidone on sexual functioning, and their findings are inconsistent.…”

Section: Discussionmentioning

confidence: 99%

The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study

Cheng,

Chen,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundAtypical antipsychotics (AAPs)-induced sexual dysfunction (SD) is a frequent issue in clinical practice, often underestimated by clinicians and not extensively researched. The current study aimed to quantify the strength of association between the use of different AAPs and SD using real-world data from the FDA Adverse Event Reporting System (FAERS), as well as investigate the receptor mechanisms that are involved.MethodsData from the FAERS database from the first quarter of 2004 to the third quarter of 2023 were queried through OpenVigil 2.1. Disproportionality analysis was estimated using the reporting odds ratio (ROR) and information component (IC) methods, and linear regression was used to investigate the relationship between ROR and receptor occupancy which was estimated using in vitro receptor binding profiles.ResultsOur analysis yielded 4839 reports that co-mentioned AAP and SD events, and the findings revealed statistical associations between 12 AAPs and SD. The highest signal value was identified for iloperidone reporting retrograde ejaculation with iloperidone (ROR = 832.09, ROR025 = 552.77; IC = 9.58, IC025 = 6.36), followed by compulsive sexual behavior with aripiprazole (ROR = 533.02, ROR025 = 435.90; IC = 7.30, IC025 = 5.97), and psychosexual disorder for aripiprazole (ROR = 145.80, ROR025 = 109.57; IC025 = 6.47, IC025 = 4.86). Different characteristics of the SD side effects in each AAPs were discovered after further data mining. Regression analysis revealed potential effects for receptor occupancy of D2, D3, and 5-HT1A receptors on ROR. However, no significant correlation persisted following sensitivity analyses.ConclusionThis is the first study to investigate the AAP-SD associations by using FAERS. In this study, we report for the first time a significant association between aripiprazole and SD based on real-world data. The study suggests that different AAPs have varying levels of association with SD, and the D2, D3, and 5-HT1A receptor occupancy may contribute to potential mechanisms. The findings of this study warrant further validation of more studies and clinical causality assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study

Cheng,

Chen,

Zhao

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, regarding psychotropic drugs, a recent study conducted by Trincheri et al highlighted that antipsychotic and antidepressant are associated with ED [ 13 ]. Among antipsychotics, first-generation antipsychotics like risperidone or paliperidone severely affect sexual function, due to dopamine antagonism (which can result in hyperprolactinemia), histaminergic, cholinergic, and alpha-adrenergic effects, as well as serotonin-mediated sexual demotivation [ 20 ]. In this regard, sexual function should be measured and monitored in patients treated with psychotropics and primary prevention should be conducted when choosing drugs, to preserve sexuality [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

The effects of non-andrological medications on erectile dysfunction: a large single-center retrospective study

Mazzilli

Zamponi

Mangini

et al. 2023

J Endocrinol Invest

View full text Add to dashboard Cite

Purpose To evaluate the association among andrological diseases at the first outpatient visit and the medications taken by patients for other comorbidities, as well as the differential impact between specific medication and relative comorbidities. Methods This is a single-center retrospective study based on subjects who referred to the Andrology Unit with a well-defined andrological diagnosis. Results A total of 3752 subjects were studied (mean age ± DS 46.2 ± 16.5 years). A total of 19 categories of andrological diseases and 110 type of medications for other comorbidities were identified. ED was the most frequent andrological pathology at the first andrological examination (28.7%), followed by infertility (12.4%). The couple of variables that were statistically significant in the univariate association analysis (p < 0.001) were: ED and (a) antihypertensives; (b) antihyperglycemics; (c) lipids-lowering; (d) psychotropics. The univariate and multivariate regression analyses confirmed the association. All the related comorbidities were also significantly associated with the univariate analysis, and all remained significantly associated with multivariate analysis. A multivariate analysis was also conducted to analyze the association between ED and the following pairs of variables “DM-antihyperglycemics”, “dyslipidemia-lipids-lowering”, and “hypertension-antihypertensives”. In all cases, the pathology, but not the specific treatment, was significantly associated with ED. Conclusion ED is significantly associated with antihypertensive, antihyperglycemic, lipid-lowering, psychotropic drugs’ intake. Anyway, ED appears to be more related to the diseases than to the specific therapies. The definitive cause/effect relationship should be established based on future prospective studies.

show abstract

Sexual Dysfunctions and Problematic Sexuality in Personality Disorders and Pathological Personality Traits: A Systematic Review

Ciocca

Stefano

Collazzoni³

et al. 2023

Curr Psychiatry Rep

View full text Add to dashboard Cite

Purpose of Review This aim of the present systematic literature review is to critically analyze problematic sexuality and sexual dysfunctions in personality disorders (PDs) and pathological personality traits. Recent Findings An initial pool of 123 studies was found, out of which 17 met the selection criteria and were therefore included. Traumatic experiences as childhood sexual abuse and adverse childhood experiences characterize the relationship between sexual behavior and PDs. From this point of view, sexual compulsivity and sexual risk behaviors, typical of BPD and ASPD, respectively, are among the pathognomonic aspects of PDs and of pathological personality traits. Summary A maladaptive personality functioning may manifest through a problematic sexuality and a sexual impairment. In this regard, traumatic life experiences may structure personality together with sexual functioning. Therefore, it would be useful to consider the relationship between trauma, sexuality, and personality in research and in the clinical setting.

show abstract

Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment

Cited by 6 publications

References 202 publications

The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study

The atypical antipsychotics and sexual dysfunction: a pharmacovigilance-pharmacodynamic study

The effects of non-andrological medications on erectile dysfunction: a large single-center retrospective study

Sexual Dysfunctions and Problematic Sexuality in Personality Disorders and Pathological Personality Traits: A Systematic Review

Contact Info

Product

Resources

About